Validation of the Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments
Validation of the Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments
复制标题
DOI：
10.1093/jnci/djx250
复制
发表时间：
2018-06-01
影响因子：
10.3
通讯作者：
Sung, Lillian
中科院分区：
文献类型：
--
作者：
Dupuis, L. Lee;Johnston, Donna L.;Sung, Lillian
背景：目的是从儿童癌症患者和儿童造血干细胞移植（HSCT）受者的角度评估儿科自我报告症状筛查工具（SSPedi）的信度和效度。方法：在这项多中心研究中，受访者是年龄在8至18岁之间的患有癌症或接受过造血干细胞移植的儿童及其父母。针对两种不同的儿童受访者人群。更多有症状的受访者正在接受癌症的积极治疗，他们住进了医院，预计三天后会住院。症状较少的应答者为急性淋巴细胞白血病维持治疗或已完成癌症治疗。儿童完成SSPedi，然后对粘膜炎、恶心、疼痛和整体生活质量的有效自我报告措施做出反应。症状较重组的儿童在三天后重复SSPedi和全球症状改变量表。Parent proxyreport是可选的。信度采用类内相关评估，而收敛效度采用Spearman相关评估。结果：入选的502名儿童中，症状较重组302名，症状较轻组200名。重测信度的类内相关系数为0.88(95%可信区间[CI] = 0.82 ~ 0.92)，评估间信度的类内相关系数为0.76 （95% CI = 0.71 ~ 0.80）。症状较重组和较轻组SSPedi评分的平均差异为7.8 （95% CI = 6.4 ~ 9.2）。SSPedi对整体症状的变化有反应。观察到所有测量之间的假设关系。结论：SSPedi是一种可靠、有效且对变化有反应的儿童癌症和移植患者自我报告症状的工具。SSPedi可用于临床和研究目的。未来的工作应侧重于整合到护理服务中。
Background: The objective was to evaluate the reliability and validity of the self-report Symptom Screening in Pediatrics Tool (SSPedi) from the perspective of children with cancer and pediatric hematopoietic stem cell transplant (HSCT) recipients.Methods: In this multicenter study, respondents were children age eight to 18 years who had cancer or had received HSCT, and their parents. Two different child respondent populations were targeted. More symptomatic respondents were receiving active treatment for cancer, admitted to the hospital, and expected to be in the hospital three days later. Less symptomatic respondents were in maintenance therapy for acute lymphoblastic leukemia or had completed cancer therapy. Children completed SSPedi and then responded to validated self-report measures of mucositis, nausea, pain, and global quality of life. Children in the more symptomatic group repeated SSPedi and a global symptom change scale three days later. Parent proxyreport was optional. Reliability was evaluated using intraclass correlations while convergent validity was evaluated using Spearman correlations.Results: Of 502 children enrolled, 302 were in the more symptomatic group and 200 were in the less symptomatic group. Intraclass correlation coefficients were 0.88 (95% confidence interval [CI] = 0.82 to 0.92) for test-retest reliability and 0.76 (95% CI = 0.71 to 0.80) for inter-rater reliability. The mean difference in SSPedi scores between more and less symptomatic groups was 7.8 (95% CI = 6.4 to 9.2). SSPedi was responsive to change in global symptoms. All hypothesized relationships among measures were observed.Conclusions: SSPedi is a self-report symptom bother tool for children with cancer and HSCT recipients that is reliable, valid, and responsive to change. SSPedi can be used for clinical and research purposes. Future work should focus on integration into care delivery.